Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Lineage Commitment01:21

Lineage Commitment

2.9K
Commitment is the  process whereby stem cells:
2.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice.

Journal of extracellular vesicles·2026
Same author

CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.

Leukemia·2026
Same author

High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.

Blood·2026
Same author

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Nature communications·2025
Same author

IL-9 secreted by leukemia stem cells induces Th1-skewed CD4+ T cells, which promote their expansion.

Blood·2024
Same author

The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.

Cancer immunology research·2024

Related Experiment Video

Updated: May 16, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Immune checkpoints regulate acute myeloid leukemia stem cells.

Chantal Reinhardt1,2,3, Adrian F Ochsenbein4,5

  • 1Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Bern, 3008, Switzerland.

Leukemia
|April 2, 2025
PubMed
Summary
This summary is machine-generated.

Acute myeloid leukemia stem cells express immune checkpoints, similar to antigen-presenting cells. These checkpoints regulate leukemia cell growth and survival, offering potential new therapeutic targets beyond current immune checkpoint inhibitors.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.1K
Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.6K

Related Experiment Videos

Last Updated: May 16, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.1K
Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.6K

Area of Science:

  • Hematology
  • Immunology
  • Cancer Biology

Background:

  • Acute myeloid leukemia stem cells (LSCs) express immune checkpoints (ICs) and MHC molecules, resembling antigen-presenting cells.
  • LSCs reside in the bone marrow, interacting with immune cells, and ICs regulate anti-tumor immunity in solid tumors.
  • Immune checkpoint inhibitors (ICIs) show limited efficacy in AML, despite IC expression on LSCs.

Purpose of the Study:

  • To review recent data on immune checkpoints in Acute Myeloid Leukemia (AML).
  • To explore the role of selected ICs from the immunoglobulin superfamily (IgSF) and tumor necrosis factor receptor superfamily (TNFRSF) in regulating LSCs.
  • To identify potential novel therapeutic targets for AML based on LSC immune checkpoint expression.

Main Methods:

  • Literature review of recent data on immune checkpoints in AML.
  • Focus on ICs regulating LSCs independently of their immune functions.
  • Analysis of ICs from IgSF and TNFRSF families.

Main Results:

  • LSCs express MHC class I/II and various immune checkpoint ligands/receptors.
  • ICs directly signal within AML blasts and LSCs, influencing self-renewal, differentiation, and expansion.
  • Expression of ICs on LSCs correlates with poorer survival outcomes.

Conclusions:

  • Immune checkpoints on LSCs play a role in leukemia progression beyond immune regulation.
  • Selected ICs, particularly from IgSF and TNFRSF, represent potential novel therapeutic targets in AML.
  • Further research into LSC-specific IC functions may improve AML treatment strategies.